Influence of phenobarbital on the psychomotor development and behaviour in preschool children with convulsions

Neuropadiatrie
|May 1, 1980
PubMed

Insights

Phenobarbital treatment for childhood epilepsy initially caused temporary behavioral issues and motor skill decline in preschoolers. These effects resolved within a year, indicating potential for long-term recovery.

Area of Science:

  • Pediatric Neurology
  • Developmental Psychology
  • Clinical Pharmacology

Background:

  • Febrile convulsions and epilepsy are common in preschool children.
  • Phenobarbital is a frequently prescribed antiepileptic medication.
  • Understanding the neurodevelopmental impact of phenobarbital in young children is crucial.

Purpose of the Study:

  • To evaluate the psychological and behavioral effects of phenobarbital in preschool children.
  • To assess the transient nature of potential drug-induced changes.
  • To correlate plasma phenobarbital levels with observed effects.

Main Methods:

  • Longitudinal study of eleven preschool children with epilepsy or febrile convulsions.
  • Administration of phenobarbital with regular psychological testing and behavioral analysis for one year.
  • Monitoring of plasma phenobarbital levels throughout the study period.

Main Results:

  • Transient deterioration in fine motor function observed in most children.
  • Behavioral disturbances were noted during the initial weeks and months of treatment.
  • All observed drug-induced changes resolved by the one-year follow-up.

Conclusions:

  • Phenobarbital can cause temporary neurodevelopmental and behavioral side effects in young children.
  • These effects appear to be transient and reversible.
  • Further research is needed to fully understand the long-term implications.

Related Concept Videos

Sedatives and Hypnotics Drugs: Barbiturates01:20

Sedatives and Hypnotics Drugs: Barbiturates

Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A key...
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...